Kala Pharmaceuticals, Inc. (0JQ2.L)
USD 4.15
(-14.43%)
USD 4.15
(-14.43%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 34.19 Million USD | -9.88% |
| 2022 | 37.93 Million USD | -52.27% |
| 2021 | 79.47 Million USD | -20.03% |
| 2020 | 99.38 Million USD | -0.47% |
| 2019 | 99.85 Million USD | 0.89% |
| 2018 | 98.97 Million USD | 725.71% |
| 2017 | 11.98 Million USD | 31.75% |
| 2016 | 9.09 Million USD | 16.72% |
| 2015 | 7.79 Million USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 22.83 Million USD | -19.92% |
| 2024 Q1 | 28.51 Million USD | -16.61% |
| 2023 Q4 | 34.19 Million USD | -4.39% |
| 2023 FY | 34.19 Million USD | -9.88% |
| 2023 Q3 | 35.75 Million USD | 6.52% |
| 2023 Q1 | 33.26 Million USD | -12.31% |
| 2023 Q2 | 33.56 Million USD | 0.91% |
| 2022 Q2 | 79.8 Million USD | -0.37% |
| 2022 Q4 | 37.93 Million USD | -11.03% |
| 2022 Q3 | 42.64 Million USD | -46.56% |
| 2022 FY | 37.93 Million USD | -52.27% |
| 2022 Q1 | 80.09 Million USD | 0.78% |
| 2021 Q4 | 79.47 Million USD | -24.42% |
| 2021 Q2 | 105.11 Million USD | 5.07% |
| 2021 FY | 79.47 Million USD | -20.03% |
| 2021 Q3 | 105.15 Million USD | 0.03% |
| 2021 Q1 | 100.04 Million USD | 0.66% |
| 2020 Q3 | 99.51 Million USD | -0.11% |
| 2020 Q2 | 99.62 Million USD | -0.12% |
| 2020 Q1 | 99.74 Million USD | -0.11% |
| 2020 FY | 99.38 Million USD | -0.47% |
| 2020 Q4 | 99.38 Million USD | -0.13% |
| 2019 Q4 | 99.85 Million USD | -0.1% |
| 2019 Q2 | 100.04 Million USD | 0.0% |
| 2019 Q1 | 100.04 Million USD | 1.08% |
| 2019 FY | 99.85 Million USD | 0.89% |
| 2019 Q3 | 99.96 Million USD | -0.09% |
| 2018 FY | 98.97 Million USD | 725.71% |
| 2018 Q4 | 98.97 Million USD | 501.47% |
| 2018 Q1 | 19.74 Million USD | 64.73% |
| 2018 Q2 | 18.1 Million USD | -8.34% |
| 2018 Q3 | 16.45 Million USD | -9.08% |
| 2017 FY | 11.98 Million USD | 31.75% |
| 2017 Q4 | 11.98 Million USD | -12.05% |
| 2017 Q3 | 13.62 Million USD | 82.01% |
| 2017 Q2 | 7.48 Million USD | -9.71% |
| 2017 Q1 | 8.29 Million USD | -8.85% |
| 2016 Q4 | 9.09 Million USD | 0.0% |
| 2016 FY | 9.09 Million USD | 16.72% |
| 2015 FY | 7.79 Million USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | 73.713% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | 40.005% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | 91.185% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | 25.175% |
| bluebird bio, Inc. | 224.41 Million USD | 84.765% |
| Cara Therapeutics, Inc. | 37.07 Million USD | 7.791% |
| Imunon, Inc. | 1.13 Million USD | -2900.984% |
| Editas Medicine, Inc. | 24.37 Million USD | -40.284% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 99.736% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 98.269% |
| Myriad Genetics, Inc. | 130.9 Million USD | 73.881% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | 86.763% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -2.994% |
| Verastem, Inc. | 40.08 Million USD | 14.708% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 99.575% |
| Waters Corporation | 2.3 Billion USD | 98.517% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 99.891% |
| Biogen Inc. | 7.18 Billion USD | 99.524% |
| Nektar Therapeutics | 112.62 Million USD | 69.643% |
| Perrigo Company plc | 3.63 Billion USD | 99.059% |
| Dynavax Technologies Corporation | 252.41 Million USD | 86.455% |
| Illumina, Inc. | 1.48 Billion USD | 97.704% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -955.693% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -3319.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | 80.323% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -45.248% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 94.235% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -2.014% |
| Evolus, Inc. | 120.35 Million USD | 71.593% |
| Adicet Bio, Inc. | 17.7 Million USD | -93.131% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -1012.232% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 98.735% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 93.183% |
| FibroGen, Inc. | 89.69 Million USD | 61.883% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 98.75% |
| OPKO Health, Inc. | 222.03 Million USD | 84.601% |
| Homology Medicines, Inc. | 43.17 Million USD | 20.812% |
| Geron Corporation | 35.05 Million USD | 2.456% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 98.541% |
| Exelixis, Inc. | 189.94 Million USD | 82.0% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -3552.778% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | 64.66% |
| Zoetis Inc. | 6.56 Billion USD | 99.479% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | 80.8% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -676.692% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 95.282% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 97.559% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 96.981% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 97.72% |
| Blueprint Medicines Corporation | 610.96 Million USD | 94.404% |
| Insmed Incorporated | 1.19 Billion USD | 97.135% |
| TG Therapeutics, Inc. | 100.11 Million USD | 65.85% |
| Incyte Corporation | 29.16 Million USD | -17.242% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 92.343% |